Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature (Endocrine DOI: 10.1007/s12020-014-0179-0);Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

Endocrine

Volumn 46, Issue 3, 2014, Pages 406-419

  Giorda, Carlo B ^a   Nada, Elisa ^b   Tartaglino, Barbara ^b  

^a ASL TO5   (Italy)

^b Chaira Medica Association   (Italy)

Author keywords

Efficacy; Hepatic impairment; Incretins or DPP 4 inhibitors or GLP 1 receptor agonists; Renal impairment; Safety

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

AREA UNDER THE CURVE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; LIVER DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; KIDNEY; LIVER; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIVER; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84904560697     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0240-z     Document Type: Erratum

References (76)

1. KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49 (2 Suppl 2): S12-154
2. C.E. Koro, B.H. Lee, S.J. Bowlin, Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin. Ther. 31(11), 2608-2617 (2009)
3. J.L. Meyers, S.D. Candrilli, B. Kovacs, Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad. Med. 123(3), 133-143 (2011)
4. National Diabetes Fact Sheet 2011. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Atlanta, GA
5. G. Penno, A. Solini, E. Bonora, C. Fondelli, E. Orsi, G. Zerbini, R. Trevisan, M. Vedovato, G. Gruden, F. Cavalot, M. Cignarelli, L. Laviola, S. Morano, A. Nicolucci, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J. Hypertens. 29(9), 1802-1809 (2011)
6. G. Pugliese, A. Solini, C. Fondelli, R. Trevisan, M. Vedovato, A. Nicolucci, Penno G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Reproducibility of albuminuria in type 2 diabetic subjects. Findings from the Renal Insufficiency And Cardiovascular Events (RIACE) study. Nephrol. Dial. Transplant. 26(12), 3950-3954 (2011)
7. G.L. Bakris, Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus. Mayo Clin. Proc. 86(5), 444-456 (2011)
8. S.K. Majumdar, S.E. Inzucchi, Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy? Endocrine 44(1), 47-58 (2013)
9. Dejager S, Schweizer A. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment. Hosp Pract (1995). 2012 Apr;40(2):7-21
10. N.V. Niemeyer, L.M. Janney, Thiazolidinedione-induced edema. Pharmacotherapy 22, 924-929 (2002)
11. A.J. Krentz, R.E. Ferner, C.J. Bailey, Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11(4), 223-241 (1994)
12. Aires Neto P, Gomes HV, Campos M. Management of hyperglycemia in patients with chronic kidney disease. J Nephrol. 2013 Jul-Aug;26(4):629-35
13. I. Mühlhauser, G. Toth, P.T. Sawicki, M. Berger, Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 14, 344-346 (1991)
14. H.B. El-Serag, T. Tran, J.E. Everharts, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460-468 (2004)
15. P.S. Hsieh, Y.J. Hsieh, Impact of liver diseases on the development of type 2 diabetes mellitus. World J. Gastroenterol. 17(48), 5240-5245 (2011)
16. I. Balik, N. Yilmaz, N. Turkcapar, H. Yasa, Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 30, 584 (1999)
17. D.J. Drucker, S.I. Sherman, F.S. Gorelick, R.M. Bergenstal, R.S. Sherwin, J.B. Buse, Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2), 428-433 (2010)
18. C.F. Deacon, Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes. Metab. 13(1), 7-18 (2011)
19. J.A. Davidson, J. Brett, A. Falahati, D. Scott, Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 17(3), 345-355 (2011)
20. A.J. Scheen, Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes. Metab. 12(8), 648-658 (2010)
21. Saxagliptin Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/001039/WC500044316. pdf. Last access January 8, 2014
22. Linagliptin Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/002110/WC500115745. pdf. Last access January 8, 2014
23. Sitagliptin Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/000722/WC500039054. pdf. Last access January 8, 2014
24. Vildagliptin Summary of Product Characteristics. http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Product-Information/human/000771/ WC500020327.pdf. Last access January 8, 2014
25. R. Christopher, P. Covington, Davenport M.P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30, 513-527 (2008)
26. P. Covington, R. Christopher, M. Davenport, P. Fleck, Q.A. Mekki, E.R. Wann, A. Karim, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 30, 499-512 (2008)
27. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy - focus on alogliptin. Drug Design, Development and Therapy 2013:7 989-1001
28. Exenatide Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/000698/WC500051845. pdf. Last access January 8, 2014
29. Liraglutide Summary of Product Characteristics. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR---Product-Information/human/001026/WC500050017. pdf
30. U. Graefe-Mody, C. Friedrich, A. Port, A. Ring, S. Retlich, T. Heise, A. Halabi, H.J. Woerle, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes. Metab. 13(10), 939-946 (2011)
31. st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24-28, 2011. Poster: 1105-P
32. D.W. Boulton, L. Li, E.U. Frevert, A. Tang, L. Castaneda, N.N. Vachharajani, D.M. Kornhauser, C.G. Patel, Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin. Pharmacokinet. 50(4), 253-265 (2011)
33. D. Boulton, A. Tang, C. Patel et al., Pharmacokinetics of the dipeptidyl peptidase-4 inhibitor saxagliptin in subjects with renal impairment. Endocrine Abstracts 20, P357 (2009)
34. A.J. Bergman, J. Cote, B. Yi, T. Marbury, S.K. Swan, W. Smith, K. Gottesdiener, J. Wagner, G.A. Herman, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 30, 1862-1864 (2007)
35. A. Karim, P. Fleck, L. Hetman et al., Single-dose pharmacokinetics of the dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment (Abstract 538-P). Diabetes 57(Suppl. 1), A160 (2008)
36. Y.L. He, B. Flannery, Y. Wang et al., The influence of renal impairment on pharmacokinetics of vildagliptin (Abstract PIII-86). Clin. Pharmacol. Ther. 81(Suppl. 1), S113 (2007)
37. Arjona Ferreira JC, Yu Q, Golm G, McCrary Sisk C, Williams-Herman D. High Correlation between Estimated Glomerular Filtration Rate and Estimated Creatinine Clearance for Sitagliptin Dose Selection in Patients with Renal Insufficiency. 2011 ADA
38. H. Linnebjerg, P.A. Kothare, S. Park, K. Mace, S. Reddy, M. Mitchell, R. Lins, Effect of renal impairment on the pharmacokinetics of exenatide. Br. J. Clin. Pharmacol. 64 (3), 317-327 (2007)
39. L.V. Jacobsen, C. Hindsberger, R. Robson, M. Zdravkovic, Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898-905 (2009)
40. Liu YH, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment. Diabetes. 2009;58(Suppl. 1):Abstract 557-P
41. Graefe-Mody U, Rose P, Retlich S, Ring A, Waldhauser L, Cinca R, Woerle HJ. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. 2012 Jan 13
42. C. Patel, L. Castaneda, U. Frevert, L. Li, D.M. Kornhauser, D.W. Boulton, Single-dose pharmacokinetics and safety of saxagliptin in subjects with hepatic impairment compared with healthy subjects (Abstract 537-P). Diabetes 57(Suppl. 1), A160 (2008)
43. E.M. Migoya, C.H. Stevens, A.J. Bergman, W.L. Luo, K.C. Lasseter, S.C. Dilzer, M.J. Davies, J.A. Wagner, G.A. Herman, Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 16, e165-e170 (2009)
44. Y.L. He, R. Sabo, J. Campestrini, Y. Wang, M. Ligueros-Saylan, K.C. Lasseter, S.C. Dilzer, D. Howard, W.P. Dole, The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur. J. Clin. Pharmacol. 63, 677-686 (2007)
45. Karim A, Fleck P, Dorsey D et al. Single-dose pharmacokinetics of alogliptin benzoate (SYR-322), a highly selective dipeptidyl peptidase-4 inhibitor, in subjects with moderate hepatic impairment (Abstract). J Clin Pharmacol 2007; 47: Abstract 107
46. A. Flint, K. Nazzal, P. Jagielski, C. Hindsberger, M. Zdravkovic, Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br. J. Clin. Pharmacol. 70 (6), 807-814 (2010)
47. Cooper M, von Eynatten M, Emser A, Patel S, Woerle HJ. Efficacy and Safety of Linagliptin in Patients With Type 2 Diabetes With or Without Renal Function Decline: Results From a Global Phase 3 Program. Poster: 1068-P, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24-28, 2011
48. S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, K.A. Dugi, Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes. Metab. 13(3), 258-267 (2011)
49. u Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, K.A. Dugi, H.J. Woerle, Safety and efficacy of linagliptin as addon therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. 13(1), 65-74 (2011)
50. D.R. Owens, R. Swallow, K.A. Dugi, H.J. Woerle, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet. Med. 28 (11), 1352-1361 (2011)
51. McGill Janet b., Lance Sloan, Jennifer Newman, Sanjay Patel, Christophe Sauce, Maximilian Von Eynatten, Hans-Juergen Woerle, Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetes Care Publish Ahead of Print, published online October 1, 2012
52. J.C. Chan, R. Scott, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams- Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes. Metab. 10, 545-555 (2008)
53. V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947-954 (2011)
54. V. Lukashevich, A. Schweizer, J.E. Foley, S. Dickinson, P.H. Groop, W. Kothny, Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag. 9, 21-28 (2013)
55. Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukashevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR \ 30). EASD 2011
56. M. Nowicki, I. Rychlik, H. Haller, M.L. Warren, L. Suchower, Gause-Nilsson I; D1680C00007 Investigators. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes. Metab. 13(6), 523-532 (2011)
57. M. Nowicki, I. Rychlik, H. Haller, M. Warren, L. Suchower, I. Gause-Nilsson, K.M. Schützer, Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int. J. Clin. Pract. 65(12), 1230-1239 (2011)
58. Y.Nakamura, M. Inagaki, T. Shimizu, K.Fujita, M.Inoue, H.Gotoh, K. Oguchi, Y. Goto, Long-Term Effects of Alogliptin Benzoate in Hemodialysis Patients with Diabetes: A 2-year Study. Nephron Clin Pract 123, 46-51 (2013). doi:10.1159/00035167
59. Ahrén B, Leguizamo Dimas A, Miossec P, Saubadu S, Aronson R. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M). Diabetes Care. 2013 Sep;36(9):2543-50. doi: 10.2337/dc12-2006. Epub 2013 Mar 27
60. Sloan L, Newman J, Sauce C, von EynattenM, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients With SevereRenal Impairment. Poster: 413-PP, 71st Scientific Sessions of the American Diabetes Association, San Diego, California, June 24-28, 2011
61. H. Yanai, H. Adachi, H. Hamasaki, Y. Masui, R. Yoshikawa, S. Moriyama, S. Mishima, A. Sako, Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis. J Clin Med Res. 4(4), 251-258 (2012)
62. W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032-1039 (2012)
63. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes. 2013 Apr 24;6:161-70. doi: 10.2147/DMSO.S28951. Print 2013
64. Alogliptin. Highlights of prescribing information http://www.accessdata. fda.gov/drugsatfda-docs/label/2013/022271s000lbl.pdf. Last access January 8, 2014
65. Pendergrass M, Fenton C, Haffner SM, Chen W. Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis. Diabetes Obes Metab 2012, Jan 23
66. U.S. Food and Drug Administration. Information for healthcare professionals; reports of altered kidney function in patients using exenatide (marketed as Byetta). Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm113705.htm. Accessed June 09, 2013
67. W.J. Weise, M.S. Sivanandy, C.A. Block, R.J. Comi, Exenatide-associated ischemic renal failure. Diabetes Care 32, 22-23 (2009)
68. H. Nandakoban, T.J. Furlong, J.R. Flack, Acute tubulointerstitial nephritis following treatment with exenatide. Diabet. Med. 30(1), 123-125 (2013). doi:10.1111/j.1464-5491.2012.03738.x
69. Y. Kaakeh, S. Kanjee, K. Boone, J. Sutton, Liraglutide-induced acute kidney injury. Pharmacotherapy 32(1), e7-e11 (2012)
70. N.R. Pinelli, C.L. Moore, S. Tomasello, Incretin-based therapy in chronic kidney disease. Adv Chronic Kidney Dis 17(5), 439-449 (2010)
71. M.C. Riddle, R. Aronson, P. Home, M. Marre, E. Niemoeller, P. Miossec, L. Ping, J. Ye, J. Rosenstock, Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care 36(9), 2489-2496 (2013)
72. J. Rosenstock, D. Raccah, L. Korányi, L. Maffei, G. Boka, P. Miossec, J.E. Gerich, Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care 36(10), 2945-2951 (2013)
73. Lixisenatide. Summary of product characteristics. http://www.ema.europa. eu/docs/it-IT/document-library/EPAR-Product-Information/human/002445/ WC500140401.pdf. Last access January 8, 2014
74. Kothny W, Schweizer A, Naik R, Groop PH, Shao Q, Lukasevich V. Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia Volume 54 (1) Springer Journals - Sep 1, 2011. A(819)
75. D.J. Cuthbertson, A. Irwin, C.J. Gardner, C. Daousi, T. Purewal, N. Furlong, N. Goenka, E.L. Thomas, V.L. Adams, S.P. Pushpakom, M. Pirmohamed, G.J. Kemp, Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 7(12), e50117 (2012)
76. Ali S, Fonseca V. Saxagliptin overview: special focus on safety and adverse effect. Expert Opinion on Drug Safety Jan 2013, Vol. 12, No. 1: 103-109